# **BIOGRAPHICAL SKETCH**

NAME: Piatek, Caroline

eRA COMMONS USER NAME (credential, e.g., agency login):

POSITION TITLE: Associate Professor

### **EDUCATION/TRAINING**

INSTITUTION AND LOCATION	DEGREE (if applicable)	Completion Date MM/YYYY	FIELD OF STUDY
Claremont McKenna College, Claremont, CA	BA	05/2005	Biology
Creighton University School of Medicine, Omaha, NE	MD	05/2009	Medical School
USC/LAC+USC Medical Center, Los Angeles, CA	Residency	06/2012	Internal Medicine
USC/LAC+USC Medical Center, Los Angeles, CA	Fellowship	05/2015	Hematology and Medical Oncology

#### A. Personal Statement

I am currently an associate professor of clinical medicine in the division of hematology at USC Norris Comprehensive Cancer Center with main research interests in cancer-associated thrombosis, immune cytopenias, and paroxysmal nocturnal hemoglobinuria.

In addition to being an investigator with a number of clinical trials conducted through Clinical Investigations Support Office (CISO), I am the co-chair of the Quality Assurance Committee Clinical Investigations Support Office and a member of the Data Safety and Monitoring Committee, Clinical Investigations Support Office.

#### **B.** Positions and Honors

# **Academic appointments:**

2015-2020 Assistant Professor of Clinical Medicine, Division of Hematology, Department of Medicine,

University of Southern California, Los Angeles, CA

2020- Associate Professor of Clinical Medicine, Division of Hematology, Department of Medicine,

University of Southern California, Los Angeles, CA

### Administrative appointments:

2018-2019	Associate Program Director, Hematology Fellowship, USC/LAC+USC Medical Center, Los Angeles, CA
2016-	Clinical Lead for Hematology Clinics, LAC+USC Medical Center, Los Angeles, CA
2018-	Co-chair, Quality Assurance Committee, Clinical Investigations Support Office, USC Norris Comprehensive Cancer Center, Los Angeles, CA
2019-	Program Director, Hematology Fellowship, USC/LAC+USC Medical Center, Los Angeles, CA
2019-	Service Chief, Hematology, USC/LAC+USC Medical Center, Los Angeles, CA
2020-	Chair, Hematology Oncology Workgroup, Department of Health Services, LAC+USC Medical
	Center, Los Angeles, CA

#### Other roles:

2016-	Small group instructor and lecturer, Hematology course of medical students, Keck School of
	Medicine, Los Angeles, CA
2018-	Member, LAC+USC Medical Center Cancer Committee, LAC+USC Medical Center, Los
	Angeles, CA
2019-	Member, Data Safety and Monitoring Committee, Clinical Investigations Support Office, USC
	Norris Comprehensive Cancer Center, Los Angeles, CA
2020	Member, Summit: Increasing Hematology Single-Board Training Tracks, American Society of
	Hematology
2021-	Member, Instutitional Review Board, University of Southern California, CA

# **Honors:**

2005	Magna Cum Laude, Claremont McKenna College, Claremont, CA
2005	Honors in Biology, Claremont McKenna College, Claremont, CA
2005	Best Biology Senior Thesis, Claremont McKenna College, Claremont, CA
2009	Medical Dean's Educational Assistance Scholarship, Creighton University School of Medicine,
	Omaha, NE
2013	Medical Oncology Fellow Research Award, USC/LAC+USC Medical Center, Los Angeles, CA
2014	Conquer Cancer Foundation Merit Award, American Society of Clinical Oncology
2014-2015	Hematology Chief Fellow, USC/LAC+USC Medical Center, Los Angeles, CA

#### C. Contributions to Science

- 1. I have a research interest in cancer-associated thrombosis and other hematology complications of cancer. I was the USC principal investigator for the CASSINI trial. This was trial investigating the use of rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer and was published in the *New England Journal of Medicine* in 2019.
  - a. **Piatek C**, O'Connell CL, Liebman HA. Treating venous thromboembolism in patients with cancer. Expert Review of Hematology. 5(2):201-9, 2012. PMID 22475288, PMCID PMC4435973
  - b. **Piatek C**, O'Connell C. Unsuspected pulmonary embolism: impact on mortality among cancer patients. Current Opinion in Pulmonary Medicine. 18(5):406-9, 2012. PMID 22759768
  - c. **Piatek CI** and Akhtari M. Management of thrombocytopenia in cancer. Oncology (Williston Park) 29(4):297-8, 2015.
  - d. **Piatek CI,** Liebman H. Thrombocytopenia in Patients with Solid Tumors or Hematologic Malignancies. Platelets in Thrombotic and Non-thrombotic Disorders. Editor: Gresele P. Cham, Switzerland, 2017.
- 2. Within non-malignant hematology, my main research interest is in immune cytopenias. In addition to the below, I also am the USC principal investigator in clinical trials in the areas of immune thrombocytopenia and warm autoimmune hemolytic anemia.

- a. Vergara-Lluri ME, **Piatek CI**, Pullarkat V, Siddiqi IN, O'Connell C, Feinstein DI, Brynes RK. Autoimmune myelofibrosis: an update on morphologic features in 29 cases and review of the literature. Human Pathology. S0046-8177(14)00315-3, 2014. PMID 25282037
- b. **Piatek CI**, Vergara-Lluri ME, Pullarkat V, Siddiqi IN, O'Connell C, Brynes RK, MD, Feinstein DI. Autoimmune Myelofibrosis— Clinical Features, Course and Outcome. Acta Heamatol. 138(3):129-137, 2017. PMID 28866671
- c. **Piatek CI**, Bocian H, Algaze S, Weitz IC, O'Connell C, Liebman HA. A Retrospective Study of the Combination of Rituximab, Cyclophosphamide and Dexamethasone for the Treatment of Relapsed/Refractory Warm Antibody Autoimmune Hemolytic Anemia. Acta Haematol. 2020;143(3):244-249. PMID: 31665725
- 3. I was the USC principal investigator for the ravulizumab registration trials for paroxysmal nocturnal hemoglobinuria (PNH). I continue to be the principial investigator on novel drug trials for the treatment PNH.
  - a. Kulasekararaj AG, Hill A, Rottinghaus ST, Langemeijer S, Wells R, Gonzalez-Fernandez FA, Gaya A, Lee JW, Ojeda Gutierrez E, Piatek CI, Szer J, Risitano A, Nakao S, Bachman E, Shafner L, Damokosh AI, Ortiz S, Röth A, Peffault de Latour R. Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study. Blood. 133(6):540-549, 2019. PMID 30510079, PMCID PMC6368201
  - b. Peipert JD, Kulasekararaj AG, Gaya A, Langemeijer SMC, Yount S, Gonzalez-Fernandez FA, Ojeda Gutierrez E, Martens C, Sparling A, Webster KA, Cella D, Tomazos I, Ogawa M, Piatek CI, Wells R, Sicre de Fontbrune F, Röth A, Mitchell L, Hill A, Kaiser K. Patient preferences and quality of life implications of ravulizumab (every 8 weeks) and eculizumab (every 2 weeks) for the treatment of paroxysmal nocturnal hemoglobinuria. PLoS One. 2020 Sep 4;15(9):e0237497. doi: 10.1371/journal.pone.0237497. PMID: 32886668; PMCID: PMC7473546.
  - c. Kulasekararaj AG, Hill A, Langemeijer S, Wells R, González Fernández FA, Gaya A, Ojeda Gutierrez E, **Piatek CI**, Mitchell L, Usuki K, Bosi A, Brodsky RA, Ogawa M, Yu J, Ortiz S, Röth A, Lee JW, Peffault de Latour R. One-year outcomes from a phase 3 randomized trial of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria who received prior eculizumab. Eur J Haematol. 2020 Dec 10. doi: 10.1111/ejh.13564. Epub ahead of print. PMID: 33301613.
- 4. During hematology/medical oncology fellowship, I had several oncology research projects. I received an ASCO Conquer Cancer Foundation Merit Award and USC Medical Oncology Fellow Research Award for my research regarding the value of routine staging imaging studies for patients with stage III breast cancer.
  - a. **Piatek CI**, Raja GL, Ji L, Gitlitz BJ, Dorff TB, Quinn DI, Hu J, El-Khoueiry AB, Pham HQ, Roman L, Garcia AA. Phase I clinical trial of temsirolimus and vinorelbine in advanced solid tumors. Cancer Chemotherapy and Pharmacology. 74(6):1227-34, 2014. PMID 25374407
  - b. **Piatek CI**, Ji L, Kaur C, Russell CA, Tripathy D, Church T, Sposto R, Sener SF, Garcia AA. Value of routine staging imaging studies for patients with stage III breast cancer. J Surg Oncol. 114(8):917-921, 2016. PMID 27642105

### D. Additional Information: Research Support and/or Scholastic Performance

I have had research support for clinical trials from, Alexion Pharmaceuticals, Apellis Pharmaceuticals, Incyte Corporation, Janssen, Oscotec Inc, and Rigel Pharmaceuticals.